Volume 86 Issue 33 | pp. 24-25
Issue Date: August 18, 2008

Productivity Lag Hits Biotech Results

Second-quarter sales reflected the lack of new products from big firms
Department: Business

IN THE ABSENCE of new growth drivers at major companies, the biotechnology industry was downright stagnant in the second quarter. Its results looked more like those offered by big pharma than the outsized sales and earnings increases that for years have been the hallmark of biotech drug companies.

The productivity lag has left some of the bigger companies, most notably Genentech, vulnerable to a takeover. If Roche succeeds in . . .

To view the rest of this content, please log in with your ACS ID.


More On This Topic

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society